Nobel honors optogenetics architects Read in browser

Thank you for reading, Test Researcher! basic Subscription UPGRADE

Mon T W Th F 5 October, 2026

Meet the emerging biotechs, funders, and pharma leaders shaping what’s next—and build the connections that can move your business forward at MassBio’s Align Summit. sponsored by MassBio

presented by The Patent Clock Is Al­ready Run­ning. Why De­vel­op­ment Speed Is Al­so a Com­mer­cial Strat­e­gy

news Nobel goes to scientists who paved the way for light-activated gene therapies CSL to pay $355M upfront to co-develop Alentis’ kidney and liver drug Epicrispr builds case for epigenetic muscle disease treatment with updated data Exclusive: Startup gets $47M for mRNA therapy manufacturing platform Bayer unpacks plans for $2.2B manufacturing site in Ohio Geographic atrophy biotech Aviceda to shut down after Phase 2 fail

Oct 08 11:00 am ET Site-central discordance in oncology trial imaging: New benchmarks and management strategies sponsored by Perceptive Imaging Oct 13 11:00 am ET Commercial excellence and AI - a ripple, wave or a tsunami sponsored by ZS Oct 15 1:00 pm ET Insights into Polycystic Kidney Disease: The Potential of Clinicogenomic Data sponsored by Natera Oct 20 11:00 am ET Intelligent oversight and orchestration: How mission control is redefining R&D decision-making sponsored by ZS Oct 21 11:00 am ET From prediction to decision: Digital twins and predictive modeling in clinical development sponsored by Flatiron Oct 22 11:00 am ET A new model for clinical research – Expanding community trial access sponsored by Parexel Oct 28 10:30 am ET The evolution of MRD: From molecular detection to clinical decisions sponsored by ABBOTT

The entire healthcare ecosystem is more Silicon Valley-ified than ever before. What tech has actually changed? Is biopharma behind? Find out, join us for Health Tech day.

ENDPOINTS PHARMA Lilly signals move into aesthetics, looking to add products for body, skin and hair FDA launches new clinical trial modernization office within CDER Peer Review Moderna, Neurocrine bring back familiar faces; Pharming CEO exits after clashing with board

in case you missed it 1. David Sinclair's latest salvo aims to stall aging with a pill